Isolation, characterization and preclinical development of human glial-restricted progenitor cells for treatment of neurological disorders
Abstract
Aim: Glial-restricted progenitor cells (GRPs), a neural cell population that gives rise to astrocytes and oligodendrocytes both in vitro and in vivo, hold great promise as a cellular therapeutic for the treatment of demyelinating and neurodegenerative diseases of the CNS. The manufacturing and characterization protocols of human-derived GRPs (hGRPs; trade name Q-Cells®) for use in a clinical setting that adhere to rigorous standards for their isolation, propagation, characterization and storage are presented. Materials & methods: hGRPs, defined by their immunoreactivity with A2B5 antibodies, were isolated from fetal cadaver forebrain tissue of mice 17–24 weeks gestational age using Miltenyi paramagnetic bead cell separation technology. GRPs were grown in a defined xenobiotic-free medium for 6 days. At harvest, hGRPs were characterized using immunocytochemical techniques. Long-term cryopreservation and storage conditions, and viability upon freeze–thaw were determined. The phenotypic differentiation potential of hGRPs was determined by implantation experiments into the CNS of shiverer mice. Results: hGRPs were isolated from over 50 neural tissues of either sex during gestational ages of 17–24 weeks. Cells expanded out to 6 days in vitro in a xenobiotic-free medium demonstrated very consistent immunocytochemical profiles. No residual antibody used in the purification process was detected after 6 days of growth in vitro. GRPs could be frozen at up to 24 million cells/ml and were over 70% viable upon freeze–thaw. Thawed hGRPs transplanted into the brain of the dysmyelinated shiverer mouse model were observed to differentiate into both glial fibrillary acidic protein-positive astrocytes and myelin basic protein-positive oligodendrocytes; no human-derived NeuN-positive neuronal cells were observed and no abnormal cell proliferation was observed. Conclusion: We demonstrate that hGRPs can be consistently obtained, propagated, cryopreserved and characterized using protocols that can be transferred to a good laboratory practice/good manufacturing practice setting for the manufacture of clinical-grade hGRP cellular therapeutics. Functional data demonstrate that cells manufactured under these conditions are able to differentiate into appropriate cellular phenotypes in an animal model of dysmyelination.
Bibliography
- 1 Windrem MS, Nunes MC, Rashbaum WK et al.: Fetal and adult human oligodendrocyte progenitor cell isolates myelinate the congenitally dysmyelinated brain. Nat. Med.10(1),93–97 (2004).
- 2 Benarroch EE: Neuron–astrocyte interactions: partnership for normal function and disease in the central nervous system. Mayo Clin. Proc.80(10),1326–1338 (2005).
- 3 Windrem MS, Schanz SJ, Guo M et al.: Neonatal chimerization with human glial progenitor cells can both remyelinate and rescue the otherwise lethally hypomyelinated shiverer mouse. Cell Stem Cell2(6),553–565 (2008).
- 4 Cao Q, Xu XM, Devries WH et al.: Functional recovery in traumatic spinal cord injury after transplantation of multineurotrophin-expressing glial-restricted precursor cells. J. Neurosci.25(30),6947–6957 (2005).
- 5 Davies JE, Huang C, Proschel C, Noble M, Mayer-Proschel M, Davies SJ: Astrocytes derived from glial-restricted precursors promote spinal cord repair. J. Biol.5(3),7 (2006).
- 6 Lepore AC, Rauck B, Dejea C et al.: Focal transplantation-based astrocyte replacement is neuroprotective in a model of motor neuron disease. Nat. Neurosci.11(11),1294–1301 (2008).
- 7 Mitsui T, Shumsky JS, Lepore AC, Murray M, Fischer I: Transplantation of neuronal and glial restricted precursors into contused spinal cord improves bladder and motor functions, decreases thermal hypersensitivity, and modifies intraspinal circuitry. J. Neurosci.25(42),9624–9636 (2005).
- 8 Dubois C, Manuguerra JC, Hauttecoeur B, Maze J: Monoclonal antibody A2B5, which detects cell surface antigens, binds to ganglioside GT3 (II3 (NeuAc)3LacCer) and to its 9-O-acetylated derivative. J. Biol. Chem.265(5),2797–2803 (1990).
- 9 Nakamura K, Kojima H, Suzuki M, Suzuki A, Tamai Y: Novel polysialogangliosides of skate brain structural determination of tetra, penta and hexasialogangliosides with a NeuAc–GalNAc linkage. Eur. J. Biochem.267(16),5198–5208 (2000).
- 10 Saito M, Kitamura H, Sugiyama K: The specificity of monoclonal antibody A2B5 to c-series gangliosides. J. Neurochem.78(1),64–74 (2001).
- 11 Dietrich J, Noble M, Mayer-Proschel M: Characterization of A2B5+ glial precursor cells from cryopreserved human fetal brain progenitor cells. Glia40(1),65–77 (2002).
- 12 Rao MS, Mayer-Proschel M: Glial-restricted precursors are derived from multipotent neuroepithelial stem cells. Dev. Biol.188(1),48–63 (1997).
- 13 Eisenbarth GS, Walsh FS, Nirenberg M: Monoclonal antibody to a plasma membrane antigen of neurons. Proc. Natl Acad. Sci. USA76(10),4913–4917 (1979).
- 14 Eisenbarth GS, Shimizu K, Bowring MA, Wells S: Expression of receptors for tetanus toxin and monoclonal antibody A2B5 by pancreatic islet cells. Proc. Natl Acad. Sci. USA79(16),5066–5070 (1982).
- 15 Merzak A, Koochekpour S, Pilkington GJ: Cell surface gangliosides are involved in the control of human glioma cell invasion in vitro. Neurosci. Lett.177(1–2),44–46 (1994).
- 16 Raff MC, Abney ER, Cohen J, Lindsay R, Noble M: Two types of astrocytes in cultures of developing rat white matter: differences in morphology, surface gangliosides, and growth characteristics. J. Neurosci.3(6),1289–1300 (1983).
- 17 Schnitzer J, Schachner M: Cell type specificity of a neural cell surface antigen recognized by the monoclonal antibody A2B5. Cell Tissue Res.224(3),625–636 (1982).
- 18 Yamamura K, Mishima Y: Antigen dynamics in melanocytic and nevocytic melanoma oncogenesis: anti-ganglioside and anti-ras p21 antibodies as markers of tumor progression. J. Invest. Dermatol.94(2),174–182 (1990).
- 19 Satoh J, Kim SU: Ganglioside markers GD3, GD2, and A2B5 in fetal human neurons and glial cells in culture. Dev. Neurosci.17(3),137–148 (1995).
- 20 Noble M, Proschel C, Mayer-Proschel M: Getting a GR(i)P on oligodendrocyte development. Dev. Biol.265(1),33–52 (2004).
- 21 Rao MS, Noble M, Mayer-Proschel M: A tripotential glial precursor cell is present in the developing spinal cord. Proc. Natl Acad. Sci. USA95(7),3996–4001 (1998).
- 22 Strathmann FG, Wang X, Mayer-Proschel M: Identification of two novel glial-restricted cell populations in the embryonic telencephalon arising from unique origins. BMC Dev. Biol.7,33 (2007).
- 23 Raff MC, Miller RH, Noble M: A glial progenitor cell that develops in vitro into an astrocyte or an oligodendrocyte depending on culture medium. Nature303(5916),390–396 (1983).
- 24 Nave KA: Neurological mouse mutants and the genes of myelin. J. Neurosci. Res.38(6),607–612 (1994).
- 25 Privat A, Jacque C, Bourre JM, Dupouey P, Baumann N: Absence of the major dense line in myelin of the mutant mouse “shiverer”. Neurosci. Lett.12(1),107–112 (1979).
- 26 Shinkai Y, Rathbun G, Lam KP et al.: RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. Cell68(5),855–867 (1992).
- 101 US FDA: Guidance, Compliance & Regulatory Information (Biologics) www.fda.gov/cber/guidelines.htm
- 102 US Department of Health and Human Services FDA, Center for Biologics Evaluation and Research: Guidance for FDA Reviewers and Sponsors: content and review of chemistry, manufacturing, and control (CMC) information for human somatic cell therapy investigational new drug applications (INDs) (2008) Link
- 201 Rao MS, Noble M, Mayer-Proschel M: US6235527 (2001).
- 202 Rao MS, Noble M, Mayer-Proschel M: US6900054 (2005).
